Literature DB >> 12816989

A role for the lymphotoxin/LIGHT axis in the pathogenesis of murine collagen-induced arthritis.

Roy A Fava1, Evangelia Notidis, Jane Hunt, Veronika Szanya, Nora Ratcliffe, Apinya Ngam-Ek, Antonin R De Fougerolles, Andrew Sprague, Jeffrey L Browning.   

Abstract

A lymphotoxin-beta (LTbeta) receptor-Ig fusion protein (LTbetaR-Ig) was used to evaluate the importance of the lymphotoxin/LIGHT axis in the development and perpetuation of arthritis. Prophylactic treatment with the inhibitor protein LTbetaR-Ig blocked the induction of collagen-induced arthritis in mice and adjuvant arthritis in Lewis rats. Treatment of mice with established collagen-induced arthritis reduced the severity of arthritic symptoms and joint tissue damage. However, in a passive model of anti-collagen Ab-triggered arthritis, joint inflammation was not affected by LTbetaR-Ig treatment precluding LT/LIGHT involvement in the very terminal immune complex/complement/FcR-mediated effector phase. Collagen-II and Mycobacterium-specific T cell responses were not impaired, yet there was evidence that the overall response to the mycobacterium was blunted. Serum titers of anti-collagen-II Abs were reduced especially during the late phase of disease. Treatment with LTbetaR-Ig ablated follicular dendritic cell networks in the draining lymph nodes, suggesting that impaired class switching and affinity maturation may have led to a decreased level of pathological autoantibodies. These data are consistent with a model in which the LT/LIGHT axis controls microenvironments in the draining lymph nodes. These environments are critical in shaping the adjuvant-driven initiating events that impact the subsequent quality of the anti-collagen response in the later phases. Consequently, blockade of the LT/LIGHT axis may represent a novel approach to the treatment of autoimmune diseases such as rheumatoid arthritis that involve both T cell and Ab components.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12816989     DOI: 10.4049/jimmunol.171.1.115

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  39 in total

1.  A role for surface lymphotoxin in experimental autoimmune encephalomyelitis independent of LIGHT.

Authors:  Jennifer L Gommerman; Keith Giza; Stuart Perper; Irene Sizing; Apinya Ngam-Ek; Cheryl Nickerson-Nutter; Jeffrey L Browning
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

Review 2.  Innate lymphoid cells in autoimmunity: emerging regulators in rheumatic diseases.

Authors:  Medya M Shikhagaie; Kristine Germar; Suzanne M Bal; Xavier Romero Ros; Hergen Spits
Journal:  Nat Rev Rheumatol       Date:  2017-02-02       Impact factor: 20.543

Review 3.  B-cell involvement in the pathogenesis of RA-is there a contribution of the sympathetic nervous system?

Authors:  Georg Pongratz; Rainer H Straub
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

Review 4.  Targeting lymphocyte activation through the lymphotoxin and LIGHT pathways.

Authors:  Carl F Ware
Journal:  Immunol Rev       Date:  2008-06       Impact factor: 12.988

Review 5.  The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games.

Authors:  Thomas Hehlgans; Klaus Pfeffer
Journal:  Immunology       Date:  2005-05       Impact factor: 7.397

6.  Targeted depletion of lymphotoxin-alpha-expressing TH1 and TH17 cells inhibits autoimmune disease.

Authors:  Eugene Y Chiang; Ganesh A Kolumam; Xin Yu; Michelle Francesco; Sinisa Ivelja; Ivan Peng; Peter Gribling; Jean Shu; Wyne P Lee; Canio J Refino; Mercedesz Balazs; Andres Paler-Martinez; Allen Nguyen; Judy Young; Kai H Barck; Richard A D Carano; Ron Ferrando; Lauri Diehl; Devavani Chatterjea; Jane L Grogan
Journal:  Nat Med       Date:  2009-06-28       Impact factor: 53.440

Review 7.  Lymphotoxin signalling in tertiary lymphoid structures and immunotherapy.

Authors:  Haidong Tang; Mingzhao Zhu; Jian Qiao; Yang-Xin Fu
Journal:  Cell Mol Immunol       Date:  2017-04-17       Impact factor: 11.530

Review 8.  Ectopic lymphoid neogenesis in rheumatic autoimmune diseases.

Authors:  Michele Bombardieri; Myles Lewis; Costantino Pitzalis
Journal:  Nat Rev Rheumatol       Date:  2017-02-09       Impact factor: 20.543

9.  Direct and indirect roles of the LTbetaR pathway in central tolerance induction.

Authors:  Mingzhao Zhu; Nicholas K Brown; Yang-Xin Fu
Journal:  Trends Immunol       Date:  2010-08-02       Impact factor: 16.687

Review 10.  Non-Canonical (RANKL-Independent) Pathways of Osteoclast Differentiation and Their Role in Musculoskeletal Diseases.

Authors:  A Sabokbar; D J Mahoney; F Hemingway; N A Athanasou
Journal:  Clin Rev Allergy Immunol       Date:  2016-08       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.